Astellas Pharma Inc. (ALPMY)
OTCMKTS · Delayed Price · Currency is USD
15.74
+0.24 (1.55%)
At close: Feb 6, 2026
Astellas Pharma Revenue
Astellas Pharma had revenue of 571.21B JPY in the quarter ending December 31, 2025, with 10.40% growth. This brings the company's revenue in the last twelve months to 2.06T, up 10.33% year-over-year. In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T with 19.25% growth.
Revenue (ttm)
2.06T JPY
Revenue Growth
+10.33%
P/S Ratio
2.12
Revenue / Employee
151.04M JPY
Employees
13,643
Market Cap
27.85B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.91T | 308.65B | 19.25% |
| Mar 31, 2024 | 1.60T | 85.05B | 5.60% |
| Mar 31, 2023 | 1.52T | 222.46B | 17.16% |
| Mar 31, 2022 | 1.30T | 46.64B | 3.73% |
| Mar 31, 2021 | 1.25T | -51.32B | -3.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
Astellas Pharma News
- 4 days ago - Astellas Pharma ADR GAAP EPS of ¥185.20, revenue of ¥1601.32B; updates full-year forecast - Seeking Alpha
- 26 days ago - Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 26 days ago - Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 4 weeks ago - Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer - Nasdaq
- 7 weeks ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
- 2 months ago - Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines - GlobeNewsWire
- 2 months ago - Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium - PRNewsWire